Bovine herpesvirus type 1 as a novel oncolytic virus

Cancer Gene Therapy

Volumn 17, Issue 5, 2010, Pages 344-355

  Rodrigues, R ^a   Cuddington, B ^a   Mossman, K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Interferon; Oncolytic virus; Therapy

Indexed keywords

INTERFERON; MESSENGER RNA; ONCOLYTIC VIRUS;

ANIMAL CELL; ARTICLE; BOVINE HERPES VIRUS; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; INNATE IMMUNITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; VIRUS REPLICATION;

ANIMALS; CATTLE; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; HERPESVIRUS 1, HUMAN; HUMANS; INTERFERON-ALPHA; NEOPLASMS; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

BOVINE HERPESVIRUS 1; HERPESVIRIDAE; HUMAN HERPESVIRUS 1;

EID: 77951131249     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.77     Document Type: Article

References (36)

1. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Onco-lytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216.
2. Cervantes-Garcia D, Ortiz-Lopez R, Mayek-Perez N, Rojas-Martinez A. Oncolytic virotherapy. Ann Hepatol 2008; 7: 34-45.
3. Stark GR. How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev 2007; 18: 419-423.
4. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263-275.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
6. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825.
7. Wang F, Ma Y, Barrett JW, Gao X, Loh J, Barton E et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol 2004; 5: 1266-1274.
8. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006; 80: 5145-5155.
9. Hummel JL, Safroneeva E, Mossman KL. The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 2005; 12: 1101-1110.
10. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-874.
11. Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006; 17: 1214-1224.
12. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859-866.
13. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747.
14. Baringer JR, Swoveland P. Recovery of herpes-simplex virus from human trigeminal ganglions. N Engl J Med 1973; 288: 648-650.
15. Corey L, Spear PG. Infections with herpes simplex viruses (1). N Engl J Med 1986; 314: 686-691.
16. Parato KA, Senger DL, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976.
17. Jones C, Chowdhury S. A review of the biology of bovine herpesvirus type 1 (BHV-1), its role as a cofactor in the bovine respiratory disease complex and development of improved vaccines. Animal health research reviews\Conference of Research Workers in Animal Diseases 2007; 8: 187-205.
18. Campadelli-Fiume G, Cocchi F, Menotti L, Lopez M. The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells. Rev Med Virol 2000; 10: 305-319.
19. Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M et al. CD155\PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 2004; 4: 73.
20. Murata T, Takashima Y, Xuan X, Otsuka H. Growth behavior of bovine herpesvirus-1 in permissive and semi-permissive cells. Virus Res 1999; 61: 29-41.
21. Hammon WM, Yohn DS, Casto BC, Atchison RW. Oncolytic Potentials of Nonhuman Viruses for Human Cancer. I. Effects of Twenty-Four Viruses on Human Cancer Cell Lines. J Natl Cancer Inst 1963; 31: 329-345.
22. Abril C, Engels M, Liman A, Hilbe M, Albini S, Franchini M et al. Both viral and host factors contribute to neurovirulence of bovine herpesviruses 1 and 5 in interferon receptor-deficient mice. J Virol 2004; 78: 3644-3653.
23. Wang F, Gao X, Barrett JW, Shao Q, Bartee E, Mohamed MR et al. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog 2008; 4: e1000099.
24. Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW et al. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 2005; 65: 9982-9990.
25. Misra V, Nelson R, Smith M. Sequence of a bovine herpesvirus type-1 glycoprotein gene that is homologous to the herpes simplex gene for the glycoprotein gB. Virology 1988; 166: 542-549.
26. Li QX, Liu G, Wong-Staal F. Oncolytic virotherapy as a personalized cancer vaccine. Int J Cancer 2008; 123: 493-499.
27. Hu J, Dong CY, Li JK, Chen DE, Liang K, Liu J. Selective in vitro cytotoxic effect of human cancer cells by bluetongue virus-10. Acta Oncol 2008; 47: 124-134.
28. Smyth M, Symonds A, Brazinova S, Martin J. Bovine enter-ovirus as an oncolytic virus: foetal calf serum facilitates its infection of human cells. Int J Mol Med 2002; 10: 49-53.
29. Hodes ME, Morgan S, Hubbard JD, Yu PL, Lukemeyer JW. Tissue culture and animal studies with an oncolytic bovine enterovirus (bovine enterovirus 1). Cancer Res 1973; 33: 2408-2414.
30. Sedmak GV, Taylor MW, Mealey Jr J, Chen TT. Oncolytic effect of bovine enterovirus on mouse and human tumours. Nat New Biol 1972; 238: 7-9.
31. Gillet L, Dewals B, Farnir F, de Leval L, Vanderplasschen A. Bovine herpesvirus 4 induces apoptosis of human carcinoma cell lines in vitro and in vivo. Cancer Res 2005; 65: 9463-9472.
32. Weinmaster GA, Misra V, McGuire R, Babiuk LA, DeClercq E. Bovid herpesvirus type-1 (infectious bovine rhinotracheitis virus)-induced thymidine kinase. Virology 1982; 118: 191-201.
33. van Oirschot JT, Kaashoek MJ, Rijsewijk FA. Advances in the development and evaluation of bovine herpesvirus 1 vaccines. Vet Microbiol 1996; 53: 43-54.
34. Jordana M, Schulman J, McSharry C, Irving LB, Newhouse MT, Jordana G et al. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am Rev Respir Dis 1988; 137: 579-584.
35. Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 1997; 57: 995-1002.
36. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ et al. Selection of highly metastatic variants of different human prostatic carcinomas using ortho-topic implantation in nude mice. Clin Cancer Res 1996; 2: 1627-1636.